A 72-year-old male presented for further evaluation and treatment of nonhealing leg ulcers. They had been present for over 7 months. The ulcers were initially treated by both his local physician and a dermatologist. Numerous topical agents. different dressings and oral antibiotics were administered, all without success. There was some concern that the ulcers were secondary to a spider bite. but this was never confirmed. There was no history of trauma. injury or previous leg ulcers. The ulcers were painful, and appeared to be increasing in size and number. A punch biop sy obtained elsewhere revealed a region of necrosis with a hemorrhagic crust, and many of the vessels had a thickened and hyalinized wall that appeared to obliterate the lumen. A working diagnosis of atrophie blanche had been made.
A 72-year-old male presented for further evaluation and treatment of nonhealing leg ulcers. They had been present for over 7 months. The ulcers were initially treated by both his local physician and a dermatologist. Numerous topical agents. different dressings and oral antibiotics were administered, all without success. There was some concern that the ulcers were secondary to a spider bite. but this was never confirmed. There was no history of trauma. injury or previous leg ulcers. The ulcers were painful, and appeared to be increasing in size and number. A punch biop sy obtained elsewhere revealed a region of necrosis with a hemorrhagic crust, and many of the vessels had a thickened and hyalinized wall that appeared to obliterate the lumen. A working diagnosis of atrophie blanche had been made.
The patient's past medical history was pertinent for one episode of deep vein thrombosis involving the right leg. He had had a transurethral resection of the prostate for benign prostatic hypertrophy and had also been treated for presumed gout for a painful. swollen right wrist 3 year s previously. The family history was pertinent for diabetes mellitus but there was no history of venous thromboembolism or leg ulcerations. His current medications included sustained-release nifedipine (30 mg/day), pentoxifylline (400 mg three times per day). one aspirin (325 mg) daily and oxycodone for pain relief.
Physical examination was pertinent for an inappropriateand erratic-behaving elderly male, older in appearance than his stated age . He complained bitterly of pain in both legs and that he was unable to sleep at night. His temperature was 37°C. blood pressure was 155/82 in both arms. pulse rate 72/min and respirations were 14/min. The heart, lung and abdominal examinations were unremarkable. The rectal exam was negative for blood or any masses.
Livedo reticularis was present on both buttocks and thighs and generalized racemosa livedo on both calves. There were five small ischemic-appearing ulcers mea suring between 1.5 em and 1.8 em in diameter on both the medial and lateral parts of his ankles ( Figures I and 2 ). All pulses were normal. The toes were cyanotic in appearance and cool to touch. He had slight right ankle edema. The neurologic exam was normal except for his behavior. His The ulcers appear worse and are much larger in appearance, despite many different treatment regimens responses to simple que stion s were at times del ayed and hes itant Laboratory studies including a complete blood count and chemistry profile were normal. His prothrombin time (PT ) was 15.3 s (normals 8.8-13.3) and the international normalized ratio (lNR) was 2.53 (normals 0.81-1. 20 ). An activated partial thromboplastin time (APTT) was 69 .7 s (normals 21.5-32.5). A magnetic resonance imaging (MRI) study demonstrated an old left occipital infarct. His anti cardiolipin antibody level s for IgG were greater than 80 IgG phospholipid units (GPL) (normal is under 10 GPL).
Discussion
Leg ulcers are a common problem often presenting to the family practitioner, general internist, dermatologist. rheumatologist. general and plastic surgeon or vascular specialist. They may pose a diagnostic dilemma. A well-organized work-up and understanding of the pathophysiology involved should direct the clinician to the correct diagnosis in most cases. The majority of ulcers may be classified as vascular in origin, with the greatest numbers attributed to venous disease (chronic venous insufficiency). Other vascular ulcers include arterial disease (ischemia). and those secondary to lymphedema. The differential diagnosis for patients presenting with ischemic leg ulcers is as follows:
warfarin skin necrosis; atheromatous embolization; atherosclerosis obliterans with trauma; spider or insect bite; vasculitis; thromboangiitis obliterans (Buerger's disease); hypertensive leg ulcer; antiphospholipid antibody syndrome; calciphylaxis.
Leg ulcers may also be seen in patients with vasculitis or an underlying hematologic disorder. with infections, or metabolic disorders such as gout or diabetes, in patients with tumors. after insect or spider bites. or factitial and secondary to illicit drugs or medications (such as warfarin).
Our patient presented with painful ischemic ulcerations that were spreading and refractory to treatment. He had a history of a previous deep vein thrombosis and gout. erratic behavior, livedo reticularis and generalized racemosa livedo on his lower extremities, cyanotic toes and a prolonged PT and APTT. The antiphospholipid antibody syndrome (APS) was suspected and later confirmed with a combination of laboratory testing. biopsy and clinical presentation. His anticardiolipin levels for IgG were greater than 80 GPL. while the normal levels are under 10 GPL.
Antiphospholipid antibody syndrome

Introduction
The APS was first described by Conley and Hartman in 1952,I although it did not then bear its current name. These two physicians described a unique anticoagulant phenomenon occurring in two patients with systemic lupus erythematosus (SLE) who demonstrated no bleeding manifestations. Both patients had a biologic false positive test for syphilis and their whole blood clotting times and prothrombin times were abnormal. The first description of thrombosis associated with APS was noted in 1963 by Bowie et al. 2 They described the presence of a circulating anticoagulant in eight of II patients with SLE. four of whom had thrombotic episodes.! Feinstein and Rapaport in 1972 3 used the term 'lupus anticoagulant' (LA) to describe this phenomenon previously reported by the above investigators, and felt it to be due to an inhibitor directed against phospholipid in the clotting cascade. In 1983. Harris and coworkers" devised a test for anti phospholipid antibodies Vascular Medicine 1996; 1: 281-285 using cardiolipin after observing an association between SLE. the biologic false positive test for syphilis and the presence of LA. The APS is now well established in the literature, and is composed of anticardiolipin antibodies. LA, reagin (the biologic false positive test for syphilis) and other antiphospholipid antibodies including antiphosphotidylinositol or antiphosphotidylserine. These are all a family of closely related immunoglobulins that interact with one or more negatively charged phospholipids in a variety of different laboratory tests.
Laboratory diagnosis
Some confusion persists in the laboratory diagnosis of APS. Two groups of tests are used to confirm the diagnosis. Presence of LA is usually identified by a prolonged APTT; however. this does not capture all patients and the APTT may be normal in up to 30% of individuals. Other tests that help identify LA include the dilute Russell viper venom test (DRVVT), platelet neutralization procedure. kaolin-clotting time, tissue thromboplastin inhibition test and, on occasion. a prolonged PT. Any combination of two of the above tests are required to confirm the presence of LA. False positive test results may occur in patients receiving anticoagulants. Not all patients with APS have a lupus anticoagulant; many will have anticardiolipin antibodies (ACA). demonstrated by a radioactive immunoassay or an ELISA (enzyme-linked immunoabsorbent assay). These are usually IgM or IgG idiotypes, although IgA should also be measured. These anticardiolipin antibodies do not prolong the APTT. Some authors have advocated measuring antiphosphotidylserine and antiphosphotidylinositol as being more specific for APS. We do not routinely perform these latter two tests at our center.
Incidence
The incidence of APS is unknown. In a study of 499 healthy blood donors. the presence of LA was found in 4% of individuals. whereas anticardiolipin antibodies were noted to be present in 5%.5 Others report the frequency of anticardiolipin antibodies in normal control populations to vary from 0 to 14%. 6 In data from 21 studies on the prevalence of LA in patients with SLE. 7 34% had this antibody. while the average prevalence of anticardiolipin antibodies in SLE was 44%. In patients with recurrent fetal loss. 10 to 40% of this select patient population will have the antibody.'
Clinical findings APS classically presents as venous or arterial thrombosis. fetal loss and thrombocytopenia. Venous events include deep vein thrombosis, renal or hepatic vein thrombosis and pulmonary embolism. but can occur in any vessel on the venous side of the circulation. Arterial events often involve the cerebral vessels, retinal vessels and heart. presenting as transient ischemic attacks, cerebrovascular accidents, multiinfarct dementia. migraine headaches. myocardial infarction. intracardiac thrombus. cardiomyopathy or valvular heart lesions. but may also present as an early graft failure following bypass surgery. or as acute leg ischemia." Obstetric complications include recurrent miscarriages. intrauterine growth retardation. and late second-or thirdtrimester fetal demise. Thrombocytopenia has been recognized as one of the cardinal features of this syndrome and persons with the LA are three times more likely to have a history of moderate to severe thrombocytopenia. Bleeding is fortunately uncommon.
Dermatologic manifestations of the APS
Dermatologic findings may be a frequent and an early marker in persons afflicted with the APS. 9 • to In Bowie's 1963 article/ involving 11 persons with a circulating anticoagulant, two individuals presented with skin findings including superficial, tender leg ulcers, livedo reticularis and painful blue toes. In 1977 Johansson et al." describing patients with a biologic false positive test for syphilis and LA, noted that 7% had painful leg ulcers around the ankle and deep vein thrombosis. In a more recent series involving 295 patients noted to have LA, Alegre? found that 34% had abnormal skin findings including: thrombophlebitis, skin ulcers, gangrene, hemorrhage and cutaneous necrosis. In this group, 37% had a history of one or more thrombotic events, including retinal vessel occlusion, renal vessel occlusion, and cerebrovascular events."
A number of other dermatologic manifestations or syndromes have now been described and may be associated with the APS. These include: pyoderma gangrenosum; painful nodules; widespread cutaneous necrosis; subungual splinter hemorrhages; discoid lupus; capillaritis; superficial thrombophlebitis; leg ulcers; gangrene; acrocyanosis; Dego's disease (also known as malignant atrophic papulosis); Beheet's syndrome; Sneddon's syndrome; livedoid vasculitis (atrophie blanche); acrocyanosis; Raynaud's phenomenon.
Our patient presented with leg ulcers, livedo reticularis and cyanosis, which are discussed in more detail below and are all well described in the literature in association with APS.
Leg ulcers
Grob and Bonerandi12 described small, painful ulcers that were oval or star-like in shape, superficial and surrounded by a purplish halo that left an atrophic scar on healing in patients with LA. Johansson et alii also described star-like ulcers that were both superficial and painful in his population with LA. Alegre? noted that 30% of the patients in his study with LA had ulcers, many which were painful. The ulcers were typically located on the pretibial area of the ankle, but were also described on the elbow or calf. They were often multiple, sharply marginated, had a necrotic center or base and healed with a white atrophic scar." Grattan ulcers were an unusual manifestation of APS and in this series noted they developed later in the course of this syndrome. Our patient had multiple small, superficial, painful ulcers that were ischemic in appearance, and when some of them eventually healed they left a white star-like scar. He also had central nervous system symptoms including erratic behavior and a change in personality.
Livedo reticularis
In 1984 Hughes 16 first drew attention to the association between livedo reticularis and the APS, and noted that a major venous or arterial occlusion often followed the onset of this entity. Livedo reticularis is caused by stagnation of blood in dilated superficial capillaries and venules, and implies pathologic changes in the larger, deeper vessels. I? It is seen on the legs most frequently; however, it may also affect the trunk and forearms. It can be classified into mild. moderate or severe.'?'!' Mild livedo retiuc1aris refers to a light purple discoloration generally limited to the legs. and felt to be a normal variant. Moderate to severe livedo reticularis involves darker purple discoloration affecting the arms and legs and may be associated with a connective tissue disease." In two series of patients, one with SLE and the other without, the prevalence of moderate to severe livedo reticularis in patients with antiphospholipid antibodies was between 19 and 25% and the severest patterns of livedo reticularis were associated with elevated levels of anticardiolipin antibodies. 10.17 In another series of 65 patients presenting with livedo reticularis, 28 were positive for anticardiolipin antibodies and there was a statistically significant difference in the incidence of cerebrovascular disease, thrombocytopenia, valvular heart lesions and fetal loss in the anticardiolipin positive group compared with those who were anticardiolipin negative. IS Livedo reticularis is reported to occur in patients with many other disease processes including: infectious diseases, after exposure to heating pads or open fires (referred to as erythema ab igne), associated with cerebrovascular disease (Sneddon's syndrome), or occurring as a reaction to cold in normal persons (sometimes referred to as cutis marmorata), or with SLE, cryoglobulinemia, polyarteritis nodosa, thrombotic thrombocytopenia purpura, essential thrombocytosis, or atheromatous embolization.
Livedo can also be differentiated into livedo reticularis and generalized racemosa livedo and some confusion exists over these terms in the literature dealing with APS. Most articles describe livedo reticularis with APS and mention generalized racemosa livedo with Sneddon's syndrome. Our patient had a reddish, purplish-blue fishnet-like discoloration, involving the buttocks and thighs. It would lighten or disappear when his legs were elevated, or warmed. This is classic livedo reticularis and has been referred to as the most common physical examination abnormality in patients with APS. 19 He also had a brownish, linear pattern present on both legs that we felt was generalized racemosa livedo ( Figure I ). This form of livedo is thought to be associated with distinct morphologic alterations of the arterial vasculature of the skin, and is the livedo pattern described in many articles dealing with Sneddon's syndrome." It does not disappear with elevation of the leg, or warming of the skin.
Cyanosis
Acrocyanosis is characterized by persistent coldness and cyanosis of the distal parts of the extremities. In the literature, cyanosis associated with APS has been reported as erythrocyanosis or acrocyanosis, although it is not entirely clear what the difference is between these two. In the study by Naldi et al'? involving 35 consecutive patients without evidence for SLE who were referred for determination of LA or ACA, 13 were LA or ACA positive, and 22 were negative and considered controls. Six of 13 patients with a positive LA or ACA had acrocyanosis, and one had erythrocyanosis. Our patient had intermittent episodes of digital cyanosis, similar to those described by Naldi et al.10
Other common dermatologic features of APS
Although not seen in our patient, many other features as listed on p. 283 have been described with APS.
Pathology and pathophysiology
Our patient's biopsy showed a noninflammatory vascular thrombosis of the small dermal vessels and subcutaneous muscular vessels. This dermal vessel thrombosis is not pathognomonic for APS, however, and may also be seen in thrombotic thrombocytopenic purpura (TIP), disseminated intravascular coagulation (DIC), cryoglobulinemia, purpura fulminans and warfarin skin necrosis.
Many pathophysiologic mechanisms have been proposed for thrombosis in patients with APS, including impairment of prostacyclin production by endothelium, increased platelet activation and adhesiveness, interference with protein C activation and abnormal antithrombin III activity. No mechanism has as of yet been well defined.
Treatment
Treatment for patients with APS who have had an arterial or venous thrombotic event is full anticoagulation. Most patients will receive heparin for the acute event, followed by long-term or lifelong therapy with warfarin. Current recommendations call for maintaining the patient's INR between three and four plus the addition of one aspirin per day, although this is not universally accepted." If the thrombotic event is a massive pulmonary embolism, or an acute ischemic limb, thrombolytic therapy with urokinase, streptokinase or tissue plasminogen activator (rt-PA) may be considered.
Treatment of the dermatologic manifestations of APS
Because the skin manifestations may be due to dermal vessel thrombosis, standard anticoagulation is a reasonable approach in patients with many of the dermatologic manifestations of APS. In those instances where anticoagulation therapy has failed, the addition of antiplatelet agents, corticosteroids, immunosuppressive agents or plasmapheresis, especially in those settings where life-threatening Vascular Medicine 1996; 1: 281-285 thrombotic conditions exist, may also be warranted.P:" These treatments aim at reducing the antibody level and have been reported to be successful in pregnancy. 24 Plasmapheresis has been tried without success in one study" and vasodilator agents and rheologic agents including pentoxifylline have also been tried. There are no good clinical trials that demonstrate consistent results when dealing with the dermatologic manifestations of APS, however, and most reports involving treatment are anecdotal. It is generally believed, however, that the risk of thrombosis may decrease when the antibodies disappear, and some have even advocated discontinuing anticoagulation therapy when this occurs." Our patient was treated with warfarin and aspirin because of his history of a previous deep vein thrombosis, erratic behavior and a cerebrovascular event as defined by his MRI, and biopsy demonstrating thrombosis in the dermal vessels. His INR was maintained above 3.0 and one daily aspirin added. He was also tried on different dressing regimens for his leg ulcers including saline wet to dry, a 3% boric acid solution, Duoderm, vaseline gauze and an Unna boot, all without success. An attempt at skin grafting was only partially successful. Our results in attempts to heal his leg ulcers reflect those of others reported in the literature, that leg ulcers in APS may be difficult to heal and are extremely painful. Unfortunately, this patient's mental status continued to deteriorate slowly over the next 18 months, finally requiring nursing home placement. He died without ever totally healing the leg ulcers.
